EverSource Wealth Advisors’s Larimar Therapeutics LRMR Stock Holding History

EverSource Wealth Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Buy	3,341 +1,635	+96%	+$6.49K	﹤0.01%	2899
2026 Q1	$7.68K	Buy	1,706 +874	+105%	+$3.49K	﹤0.01%	3062
2025 Q4	$3.17K	Sell	832 -93	-10%	-$362	﹤0.01%	3319
2025 Q3	$2.99K	Buy	925 +191	+26%	+$716	﹤0.01%	3377
2025 Q2	$2.12K	Buy	734 +536	+271%	+$1.24K	﹤0.01%	3492
2025 Q1	$426	Buy	+198	New	+$626	﹤0.01%	3510

Other funds holding LRMR

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

NLP

Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return

EverSource Wealth Advisors's LRMR Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Larimar Therapeutics (LRMR) stake by 96% in Q2 2026, buying an estimated $6.49K and bringing the position to 3,341 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

EverSource Wealth Advisors first reported a position in LRMR in Q1 2025 and has held it in 6 quarters since. 31 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

EverSource Wealth Advisors held 3,341 shares of Larimar Therapeutics worth $10.2K as of Q2 2026.
EverSource Wealth Advisors bought 1,635 Larimar Therapeutics shares in Q2 2026, an estimated $6.49K.
Larimar Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2899 holding.
EverSource Wealth Advisors first reported a position in Larimar Therapeutics in Q1 2025 and has held it in 6 quarters since.
31 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.